Roche moves experimental obesity drug CT-996 into pivotal trials after mid-stage success.[1][3] Acquired by Carmot Therapeutics, this oral drug mimics the GLP-1 hormone in the gut and is designed to treat both obesity and type 2 diabetes.[1][3] In a phase 1 study, patients lost an average of 7.3% of body weight after four weeks of treatment, compared to 1.2% in the placebo group.[1][3] Results were not affected by fasting or high-fat meals.[1] The drug has shown a favorable safety profile comparable to similar GLP-1 drugs.[3] Roche plans to release more data in the coming months and launch a phase 2 study next year.[1] CT-996 is Roche's second experimental obesity drug to achieve clinically significant weight loss.[1]